PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE Drug Patent Profile

Which patents cover Pioglitazone Hydrochloride And Glimepiride, and what generic alternatives are available?

Pioglitazone Hydrochloride And Glimepiride is a drug marketed by Chartwell Rx and is included in one NDA.

The generic ingredient in PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.

Summary for PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	20
DailyMed Link:	PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE at DailyMed

Recent Clinical Trials for PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Seoul National University Hospital	Phase 4
Kanazawa University	Phase 4
Kowa Company, Ltd.	Phase 4

See all PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE clinical trials

US Patents and Regulatory Information for PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	201049-001	Jan 4, 2013	AB	RX	No	No
Chartwell Rx	PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE	glimepiride; pioglitazone hydrochloride	TABLET;ORAL	201049-002	Jan 4, 2013	AB	RX	No	No

Pioglitazone Hydrochloride and Glimepiride Market Dynamics and Financial Trajectory

Last updated: August 7, 2026

Pioglitazone hydrochloride and glimepiride is a mature fixed-dose combination for type 2 diabetes, marketed in the United States as Duetact and available from generic manufacturers. Its commercial value has shifted from originator-brand revenue to low-cost generic volume. The combination has no meaningful U.S. market exclusivity remaining, while its clinical use is constrained by hypoglycemia, weight gain, edema, heart-failure warnings, and competition from metformin, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and insulin.

The product remains relevant in price-sensitive markets where low acquisition cost matters more than cardiovascular, renal, or weight-loss benefits. Its long-term financial trajectory is therefore stable but low growth, with limited pricing power and modest litigation risk.

What is pioglitazone hydrochloride and glimepiride?

Pioglitazone hydrochloride and glimepiride combines two oral antihyperglycemic agents with different mechanisms:

Component	Pharmacologic class	Primary action	Principal risks
Pioglitazone hydrochloride	Thiazolidinedione	Improves insulin sensitivity through PPAR-gamma activation	Edema, weight gain, heart failure, fractures
Glimepiride	Sulfonylurea	Stimulates pancreatic insulin secretion	Hypoglycemia, weight gain

The branded U.S. product, Duetact, was approved by the FDA in 2006. It was indicated as an adjunct to diet and exercise for adults with type 2 diabetes who required treatment with both pioglitazone and glimepiride. The product was designed for patients already receiving either component or for patients inadequately controlled on one component alone.

Available Duetact strengths have included:

• Pioglitazone 30 mg/glimepiride 2 mg
• Pioglitazone 30 mg/glimepiride 4 mg
• Pioglitazone 45 mg/glimepiride 4 mg

The product is not indicated for type 1 diabetes or diabetic ketoacidosis. The FDA label carries a boxed warning concerning congestive heart failure associated with pioglitazone-containing therapy.[1]

What is the FDA regulatory status of Duetact and generic pioglitazone-glimepiride?

Duetact received FDA approval under New Drug Application 021925. Generic versions have entered the U.S. market through abbreviated new drug applications after the relevant approval and exclusivity barriers expired.

The regulatory profile is now mature:

Regulatory issue	Current commercial effect
New chemical entity exclusivity	Expired
Fixed-combination exclusivity	Expired
U.S. brand market protection	No longer commercially material
Generic substitution	Available or historically available depending on strength and manufacturer
FDA safety restrictions	Continue to affect prescribing
Biosimilar pathway	Not applicable because the product is a small-molecule drug

The product is not a biologic and therefore does not face biosimilar competition. Its competitive threat comes from abbreviated new drug applications, therapeutic substitution, and newer branded diabetes therapies.

The FDA labeling for pioglitazone requires warnings concerning fluid retention and heart failure. Glimepiride labeling emphasizes hypoglycemia risk, particularly in older patients, patients with renal or hepatic impairment, and those with irregular food intake.[1,2]

When does pioglitazone-glimepiride lose exclusivity?

U.S. commercial exclusivity for the fixed-dose combination has already expired. The underlying active ingredients are also long off patent.

Pioglitazone was developed and commercialized by Takeda as Actos. Glimepiride was commercialized in the United States as Amaryl, initially by Aventis and later by Sanofi. The compound-level patent estates for both active ingredients expired years ago, allowing broad generic competition.

The key exclusivity milestones were:

Asset	Originator	Commercial history	Current status
Pioglitazone	Takeda	Actos	Generic market
Glimepiride	Aventis/Sanofi	Amaryl	Generic market
Fixed-dose combination	Takeda	Duetact	Generic market
Pioglitazone-glimepiride patents	Originator-related	Historical formulation and combination protection	No apparent active U.S. barrier of commercial significance

The relevant U.S. regulatory source is the FDA Orange Book, which lists approved drug products, patent certifications, and applicable exclusivity information.[3] A current transaction or launch decision should rely on the latest Orange Book record and the specific strength being evaluated because patent listings and product availability can vary by dosage form.

What patents protect pioglitazone hydrochloride and glimepiride?

The commercially important patent protection has expired for the active ingredients and the fixed-dose combination.

Historically, protection covered several categories:

Pioglitazone compound patents

Pioglitazone was protected through early compound and pharmaceutical-use patents associated with Takeda. Those rights supported Actos sales before generic entry. The broad compound protection is no longer a meaningful barrier to U.S. generic manufacture.

Glimepiride compound patents

Glimepiride was protected through originator patents associated with the Amaryl franchise. Those rights also expired before the current mature generic market developed.

Fixed-dose formulation patents

The Duetact combination could have relied on patents covering:

• The combination of pioglitazone and glimepiride
• Tablet composition
• Strength-specific dosage ratios
• Manufacturing or formulation parameters
• Therapeutic use in patients inadequately controlled on monotherapy

These rights no longer create a material U.S. market barrier. Any residual patent question would be strength-specific and jurisdiction-specific rather than a broad obstacle to generic competition.

How many patents cover pioglitazone-glimepiride today?

No active U.S. patent estate appears to provide the combination with meaningful commercial exclusivity. The product’s economic protection is based on manufacturing scale, distribution, regulatory compliance, and formulary access rather than patent exclusivity.

The distinction matters:

• Patent expiry removes legal exclusivity.
• ANDA approval enables generic substitution.
• Actual market entry depends on manufacturing economics, supply reliability, and wholesaler access.
• Foreign markets may have different patent histories and registration requirements.

For licensing or acquisition purposes, the relevant intellectual-property value is more likely to reside in manufacturing know-how, regional registrations, trademarks, and supply contracts than in blocking patents.

What was the Paragraph IV challenge history?

Generic applicants could challenge listed patents through Paragraph IV certifications under the Hatch-Waxman Act. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed.

The commercial significance of any historical Paragraph IV litigation has largely ended because:

1. The underlying active ingredients are long genericized.
2. The fixed-dose product has been exposed to generic competition.
3. Brand prescribing has declined relative to newer therapies.
4. Any 180-day generic exclusivity period would have expired.

A historical litigation review should distinguish between patent cases involving Actos or Amaryl individually and cases involving the Duetact fixed-dose combination. Actos-related litigation also included major product-liability matters concerning bladder cancer allegations, which were separate from ordinary Hatch-Waxman patent disputes. Those matters affected Takeda’s broader pioglitazone economics but did not preserve market exclusivity for the combination.

What is the Orange Book status of Duetact?

The Orange Book is the controlling U.S. source for listed patents and generic approval status. Duetact’s commercial position is consistent with an off-patent combination product:

• No current brand-only market protection is economically significant.
• Generic versions may be approved by strength.
• Patent listings, if any remain, must be evaluated by product and dosage strength.
• Orange Book status does not guarantee that every listed strength is continuously available from every generic manufacturer.

The practical market question is not whether generic entry is legally possible. It is whether a manufacturer can achieve acceptable margins after active pharmaceutical ingredient costs, tableting, packaging, quality controls, regulatory fees, rebates, and wholesaler discounts.

What formulations are protected by pioglitazone-glimepiride patents?

The principal formulation is an immediate-release oral tablet. The combination does not have the high-value delivery-system profile seen in extended-release, injectable, depot, transdermal, or device-based products.

Potential formulation claims historically included:

• Specific pioglitazone-to-glimepiride ratios
• Tablet excipient systems
• Dissolution characteristics
• Stability profiles
• Manufacturing processes
• Separate or combined dosing regimens

These formulations are commercially simple compared with modified-release or biologic products. Manufacturing know-how can support quality and supply consistency, but it is unlikely to justify premium pricing in a mature generic market unless a manufacturer has a differentiated dosage form or a protected regional registration.

How strong is the patent estate for pioglitazone-glimepiride?

The current patent estate is weak from a blocking-rights perspective and limited from a licensing perspective.

Patent-estate criterion	Assessment
Active ingredient exclusivity	Expired
Fixed-dose combination exclusivity	Expired
Formulation differentiation	Limited
Manufacturing barriers	Low to moderate
Regulatory complexity	Moderate
Litigation exposure	Low for patent enforcement; historical product-liability exposure remains relevant to pioglitazone
Licensing value	Low unless tied to regional rights, supply, or differentiated formulation

A buyer should not value this product as a patent-protected asset. Its value is closer to that of a mature multisource generic with established physician familiarity and low-cost positioning.

What is the competitive landscape for pioglitazone-glimepiride?

The combination competes against both other oral combinations and newer therapies.

Competitive category	Examples	Competitive advantage
Metformin combinations	Metformin plus sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor	Broad guideline use and low cost for metformin-based regimens
DPP-4 inhibitors	Sitagliptin, linagliptin	Lower hypoglycemia risk and weight neutrality
SGLT2 inhibitors	Empagliflozin, dapagliflozin	Cardiovascular and renal outcome benefits in selected patients
GLP-1 receptor agonists	Semaglutide, dulaglutide, liraglutide	Glycemic efficacy and weight reduction
Insulin	Basal and basal-bolus regimens	High glucose-lowering potency
Pioglitazone combinations	Pioglitazone-metformin and other generic combinations	Low cost and insulin-sensitizing activity

Clinical guidelines increasingly prioritize agents with cardiovascular, renal, or weight benefits for patients with relevant comorbidities. Pioglitazone-glimepiride lacks the outcome-positioning and commercial promotion of SGLT2 inhibitors and GLP-1 receptor agonists.[4]

Its strongest niche is a patient who needs inexpensive oral therapy, has no meaningful heart-failure risk, and can tolerate the weight-gain and hypoglycemia liabilities.

What is the financial trajectory of pioglitazone-glimepiride?

The financial trajectory has four phases:

Originator launch

Takeda initially captured value through Duetact branding, physician promotion, and the broader Actos franchise. Revenue benefited from patent-protected pioglitazone economics and combination convenience.

Generic erosion

Generic entry reduced price and shifted prescribing away from the branded product. The combination’s revenue decline was accelerated by generic versions of both components, which allowed physicians and payers to use separate tablets at lower cost.

Mature generic phase

The product now operates in a low-price, low-margin market. Revenue is generally generated through unit volume rather than price expansion. Manufacturers compete on:

• Wholesale acquisition cost
• Rebate terms
• Supply reliability
• National formulary placement
• Pharmacy benefit manager contracts
• State Medicaid access
• Product availability by strength

Long-term steady state

Volume may persist in lower-income markets and among patients with limited insurance coverage. Revenue growth is unlikely without a new formulation, geographic expansion, or a branded repositioning strategy.

Public-company filings generally do not report pioglitazone-glimepiride revenue as a standalone product. Takeda reports portfolio and therapeutic-area results at broader levels, while generic manufacturers often disclose product revenue only in aggregate. A standalone market-size figure therefore should not be inferred from company filings.[5]

What generic entry risks exist for pioglitazone-glimepiride?

Generic launch risk is low from a patent perspective but high from a commercial-return perspective.

Legal risk

The product has no apparent blocking U.S. patent barrier of practical importance. New entrants would typically face routine ANDA requirements rather than a complex patent litigation pathway.

Manufacturing risk

The main barriers include:

• API sourcing
• Content uniformity
• Dissolution compliance
• Stability data
• FDA inspection performance
• Recall exposure
• Shortage management

Commercial risk

A new entrant may face rapid price compression if several suppliers sell the same strengths. The 30 mg/4 mg and 45 mg/4 mg strengths may have different competitive dynamics from the 30 mg/2 mg strength because supplier participation and prescription volume can vary.

Clinical risk

Safety concerns can limit demand even when price is attractive. Pioglitazone is unsuitable for some patients with heart failure or fluid-retention risk. Glimepiride creates hypoglycemia concerns that reduce its appeal relative to newer agents.

Which companies are challenging the Duetact franchise?

The franchise is challenged primarily by generic manufacturers and therapeutic substitutes rather than by a single branded competitor.

Potential generic suppliers have included companies operating in U.S. abbreviated-drug markets, such as large Indian and U.S.-based generic manufacturers. Supplier participation can change over time because products may be approved but not marketed, discontinued, or temporarily unavailable.

The more important competitive challenge comes from manufacturers of:

• Jardiance and other SGLT2 inhibitors
• Ozempic, Rybelsus, and other semaglutide products
• Trulicity and other GLP-1 receptor agonists
• Januvia and other DPP-4 inhibitors
• Generic metformin combinations

These therapies compete for treatment sequencing, payer coverage, and physician attention rather than only for the same fixed-dose prescription.

What is the revenue exposure for manufacturers?

For the originator, direct Duetact exposure is immaterial relative to the historical Actos franchise and broader pharmaceutical portfolio. For generic manufacturers, exposure is usually small on a company-wide basis but can matter at the product level if the company has:

• Limited competition in a specific strength
• A preferred Medicaid contract
• Reliable API supply
• A niche market in a country with limited access to newer therapies
• A portfolio strategy focused on chronic oral medicines

The revenue profile is defensive rather than growth-oriented. Forecast assumptions should use declining or flat price, stable-to-declining volume, and low probability of premium pricing.

What licensing deals affect pioglitazone-glimepiride?

The major economic rights historically centered on originator commercialization and generic distribution. No widely recognized current licensing structure gives the combination a premium valuation in the U.S.

Potential transaction value would more likely arise from:

• Regional marketing rights
• Contract manufacturing
• Authorized-generic supply
• Bundling with other diabetes products
• Registration dossiers in emerging markets
• Distribution rights in public-health channels

A transaction based solely on U.S. patent exclusivity would have weak support because the product is already mature and multisource.

What patent litigation affects pioglitazone-glimepiride?

Current patent litigation risk is limited. Historical disputes connected to pioglitazone include product-liability litigation involving bladder-cancer allegations and regulatory labeling issues. Those matters differ from patent cases and should be modeled separately.

For a generic manufacturer, the more relevant legal risks are:

• ANDA certification disputes
• Manufacturing compliance actions
• False-claims or pricing investigations
• Product-liability claims
• Supply-contract disputes
• Trademark and trade-dress claims

Patent litigation is unlikely to be the primary determinant of value.

How does pioglitazone-glimepiride compare with newer diabetes combinations?

Factor	Pioglitazone-glimepiride	SGLT2 or GLP-1-based therapy
Acquisition cost	Low	Often substantially higher
Weight effect	Weight gain risk	Weight loss or relative weight neutrality
Hypoglycemia	Meaningful risk from glimepiride	Lower risk when used without insulin or sulfonylurea
Cardiovascular positioning	No comparable class-wide advantage	Stronger evidence for selected agents
Renal positioning	Limited	Stronger for selected SGLT2 inhibitors
Patent status	Mature generic	Many products remain branded or partly protected
Commercial growth	Low	Higher, although subject to pricing and access pressure

The combination remains economically viable where affordability dominates clinical differentiation. It is poorly positioned for premium markets that reward weight reduction or cardiorenal outcomes.

Key Takeaways

• Pioglitazone hydrochloride and glimepiride is a mature oral combination marketed in the U.S. as Duetact.
• U.S. exclusivity has expired, and generic competition defines the market.
• The product has no biosimilar risk because it is a small-molecule drug.
• Patent value is low; manufacturing, registration, and distribution rights matter more.
• Revenue has moved from originator-brand economics to low-margin generic volume.
• The main clinical constraints are hypoglycemia, weight gain, edema, heart failure, and fracture risk.
• SGLT2 inhibitors and GLP-1 receptor agonists are the principal strategic competitors.
• Patent litigation is less important than regulatory compliance, supply reliability, and payer access.
• Commercial upside is most plausible in price-sensitive geographic markets or through efficient generic manufacturing.

FAQs

Is pioglitazone-glimepiride still prescribed?

Yes. Use persists among patients needing inexpensive oral therapy, particularly where newer agents are unavailable or unaffordable. Prescribing is constrained by safety and tolerability concerns.

Is Duetact the same as taking pioglitazone and glimepiride separately?

The active ingredients are the same, but a fixed-dose tablet reduces pill burden. Separate tablets may offer more flexible dose adjustment and can cost less.

Can pioglitazone-glimepiride cause low blood sugar?

Yes. Glimepiride increases insulin secretion and can cause hypoglycemia, especially when meals are skipped or the medicine is combined with other glucose-lowering agents.

Is pioglitazone-glimepiride appropriate for patients with heart failure?

Pioglitazone-containing treatment may worsen fluid retention and heart failure. The FDA labeling includes a boxed warning, making heart-failure status a central prescribing consideration.[1]

Does pioglitazone-glimepiride have investment-grade growth potential?

The product generally has limited growth potential in the United States. Investment value is more likely to come from manufacturing efficiency, regional access, or portfolio bundling than from patent-driven pricing power.

References

1. U.S. Food and Drug Administration. (2023). Duetact (pioglitazone hydrochloride and glimepiride) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Glimepiride prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178.

5. Takeda Pharmaceutical Company Limited. (2024). Annual report and Form 20-F. Takeda Pharmaceutical Company Limited.